Shenzhen Kangtai Biological Products Co Ltd (300601) - Total Assets
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) holds total assets worth CN¥13.99 Billion CNY (≈ $2.05 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Shenzhen Kangtai Biological Products Co total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Shenzhen Kangtai Biological Products Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 300601 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Kangtai Biological Products Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shenzhen Kangtai Biological Products Co Ltd's total assets of CN¥13.99 Billion consist of 42.5% current assets and 57.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 1.8% |
| Accounts Receivable | CN¥2.58 Billion | 18.3% |
| Inventory | CN¥681.09 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥585.39 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300601 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Kangtai Biological Products Co Ltd's current assets represent 42.5% of total assets in 2025, an increase from 40.2% in 2012.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2025, down from 19.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 19.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 18.3% of total assets.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Kangtai Biological Products Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Shenzhen Kangtai Biological Products Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.87 | 2.68 | 2.28 |
| Quick Ratio | 2.54 | 2.36 | 1.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.88 Billion | CN¥3.90 Billion | CN¥3.04 Billion |
Shenzhen Kangtai Biological Products Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Kangtai Biological Products Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | CN¥14.10 Billion |
| Market Capitalization | $1.88 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Kangtai Biological Products Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shenzhen Kangtai Biological Products Co Ltd's assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
The table below shows the annual total assets of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥14.10 Billion ≈ $2.06 Billion |
-3.22% |
| 2024-12-31 | CN¥14.56 Billion ≈ $2.13 Billion |
-3.46% |
| 2023-12-31 | CN¥15.09 Billion ≈ $2.21 Billion |
+9.42% |
| 2022-12-31 | CN¥13.79 Billion ≈ $2.02 Billion |
-2.56% |
| 2021-12-31 | CN¥14.15 Billion ≈ $2.07 Billion |
+47.62% |
| 2020-12-31 | CN¥9.58 Billion ≈ $1.40 Billion |
+142.50% |
| 2019-12-31 | CN¥3.95 Billion ≈ $578.36 Million |
+18.31% |
| 2018-12-31 | CN¥3.34 Billion ≈ $488.87 Million |
+51.12% |
| 2017-12-31 | CN¥2.21 Billion ≈ $323.50 Million |
+38.09% |
| 2016-12-31 | CN¥1.60 Billion ≈ $234.26 Million |
+20.02% |
| 2015-12-31 | CN¥1.33 Billion ≈ $195.18 Million |
-0.61% |
| 2014-12-31 | CN¥1.34 Billion ≈ $196.39 Million |
+21.25% |
| 2013-12-31 | CN¥1.11 Billion ≈ $161.97 Million |
-2.62% |
| 2012-12-31 | CN¥1.14 Billion ≈ $166.34 Million |
-- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more